{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:32:57Z","timestamp":1693197177763},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The successful treatment of surgical fungal infections depends of a timely and adequate source control alongside with the use of prompt systemic antifungals. The main challenge of antifungal use in critically ill surgical patients is to find a balance between rational versus indiscriminate use in order to accomplish an antifungal stewardship program.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Surgical fungal infections represent an important burden in the daily clinical activity in many ICUs. The efficacy of the available antifungal drugs has not been adequately assessed in randomized controlled trials with surgical fungal infections in ICU patients. Most clinical experience is limited to case reports or uncontrolled case series. Due to the lack of adequate scientific evidence to assess the role of the different antifungals in surgical ICU patients, it is usually suggested to follow the recommendations for invasive candidiasis and candidemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Antifungal use in the surgical patients admitted to an ICU is a complex matter and there are several elements to consider like the presence of septic shock and multiorgan failure, local epidemiology and antifungal resistance, among others. The proper use of antifungals alongside early recognition and prompt source control, are critical factors for improved outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aco.0000000000000813","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:31:56Z","timestamp":1574901116000},"page":"131-138","source":"Crossref","is-referenced-by-count":2,"title":["Antifungal use in the surgical ICU patient"],"prefix":"10.1097","volume":"33","author":[{"given":"Pedro","family":"P\u00f3voa","sequence":"first","affiliation":[{"name":"Polyvalent Intensive Care Unit, S\u00e3o Francisco Xavier Hospital, Centro Hospitalar de Lisboa Ocidental"},{"name":"NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal"},{"name":"Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, OUH Odense University Hospital, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Coelho","sequence":"additional","affiliation":[{"name":"Polyvalent Intensive Care Unit, S\u00e3o Francisco Xavier Hospital, Centro Hospitalar de Lisboa Ocidental"},{"name":"NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nora","sequence":"additional","affiliation":[{"name":"Polyvalent Intensive Care Unit, S\u00e3o Francisco Xavier Hospital, Centro Hospitalar de Lisboa Ocidental"},{"name":"NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Critical Care Medicine"},{"name":"Multidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, Dublin, Ireland"},{"name":"Pulmonary Intensive Care Unit, Respiratory Institute, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, CIBERes, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230827","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R2-20230827","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"R3-20230827","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","article-title":"ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013 - a study from the REA-RAISIN network","volume":"75","author":"Baldesi","year":"2017","journal-title":"J Infect"},{"key":"R4-20230827","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1148\/radiology.217.3.r00dc35647","article-title":"Pulmonary infections in immunocompromised hosts: the importance of correlating the conventional radiologic appearance with the clinical setting","volume":"217","author":"Oh","year":"2000","journal-title":"Radiology"},{"key":"R5-20230827","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1001\/jama.1987.03400200047006","article-title":"Immunodeficiency diseases","volume":"258","author":"Buckley","year":"1987","journal-title":"JAMA"},{"key":"R6-20230827","doi-asserted-by":"crossref","first-page":"S3398","DOI":"10.21037\/jtd.2018.08.85","article-title":"Surgical management of nonmycobacterial fungal infections","volume":"10","author":"Beamer","year":"2018","journal-title":"J Thorac Dis"},{"key":"R7-20230827","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10156-007-0595-7","article-title":"Current challenges in the management of invasive fungal infections","volume":"14","author":"Lai","year":"2008","journal-title":"J Infect Chemother"},{"key":"R8-20230827","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"R9-20230827","doi-asserted-by":"crossref","first-page":"e1002870","DOI":"10.1371\/journal.ppat.1002870","article-title":"Antifungal drug discovery: something old and something new","volume":"8","author":"Butts","year":"2012","journal-title":"PLoS Pathog"},{"key":"R10-20230827","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1469-0691.2010.03360.x","article-title":"A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units","volume":"17","author":"Montravers","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R11-20230827","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.qco.0000433309.21148.f7","article-title":"Intra-abdominal fungal infections","volume":"26","author":"Rebolledo","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"R13-20230827","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","article-title":"ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients","volume":"45","author":"Martin-Loeches","year":"2019","journal-title":"Intensive Care Med"},{"key":"R14-20230827","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/CCM.0b013e318236f297","article-title":"Systemic antifungal therapy in critically ill patients without invasive fungal infection\u2217","volume":"40","author":"Azoulay","year":"2012","journal-title":"Crit Care Med"},{"key":"R15-20230827","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/CCM.0000000000002698","article-title":"Antifungal prevention of systemic candidiasis in immunocompetent ICU adults: systematic review and meta-analysis of clinical trials","volume":"45","author":"Dupont","year":"2017","journal-title":"Crit Care Med"},{"key":"R16-20230827","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","article-title":"Amphotericin B","volume":"68","author":"Lemke","year":"2005","journal-title":"Appl Microbiol Biotechnol"},{"key":"R17-20230827","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1381612013398031","article-title":"Lipid-based antifungal agents: current status","volume":"7","author":"Arikan","year":"2001","journal-title":"Curr Pharm Des"},{"key":"R18-20230827","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1128\/AAC.48.11.4453-4456.2004","article-title":"In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies","volume":"48","author":"Di Bonaventura","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20230827","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","author":"Andes","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"R20-20230827","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.01030-07","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans","volume":"52","author":"Venisse","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20230827","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157488407779422311","article-title":"Clinical pharmacokinetics of systemically administered antimycotics","volume":"2","author":"Bellmann","year":"2007","journal-title":"Curr Clin Pharmacol"},{"key":"R22-20230827","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/cc9414","article-title":"Treatment of candidemia in adult patients without neutropenia--an inconvenient truth","volume":"15","author":"Povoa","year":"2011","journal-title":"Crit Care"},{"key":"R23-20230827","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.201304-0769LE","article-title":"Amphotericin B in severe fungal infections: a critical reappraisal of the evidence","volume":"188","author":"Povoa","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R24-20230827","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R25-20230827","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20230827","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/ajrccm.187.6.661","article-title":"Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications","volume":"187","author":"Dreyfuss","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20230827","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-20230827","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"R29-20230827","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1054\/drup.1999.0112","article-title":"Molecular aspects of azole antifungal action and resistance","volume":"2","author":"Lamb","year":"1999","journal-title":"Drug Resist Updat"},{"key":"R30-20230827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.32.1.1","article-title":"Azole antifungal agents: emphasis on new triazoles","volume":"32","author":"Saag","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20230827","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2003.09.008","article-title":"In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program","volume":"48","author":"Pfaller","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R32-20230827","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"Gonzalez","year":"2005","journal-title":"Med Mycol"},{"key":"R33-20230827","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1128\/JCM.00409-07","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R34-20230827","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/JCM.00946-09","article-title":"Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"R35-20230827","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s40588-015-0015-1","article-title":"Update on antifungal drug resistance","volume":"2","author":"Perlin","year":"2015","journal-title":"Curr Clin Microbiol Rep"},{"key":"R36-20230827","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00203-019-01618-y","article-title":"Molecular identification of clinical and environmental avian Aspergillus isolates","volume":"201","author":"Sabino","year":"2019","journal-title":"Arch Microbiol"},{"key":"R37-20230827","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.coph.2007.05.004","article-title":"Pharmacodynamic implications for use of antifungal agents","volume":"7","author":"Lewis","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"R38-20230827","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199039060-00006","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses","volume":"39","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"R39-20230827","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R40-20230827","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R41-20230827","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"(Suppl 1)","key":"R42-20230827","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R43-20230827","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie","year":"1996","journal-title":"Clin Infect Dis"},{"key":"R44-20230827","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R45-20230827","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echinocandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R46-20230827","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1128\/JCM.41.12.5729-5731.2003","article-title":"Caspofungin activity against clinical isolates of fluconazole-resistant Candida","volume":"41","author":"Pfaller","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R47-20230827","first-page":"2719","article-title":"Effects of caspofungin against Candida guilliermondii and Candida parapsilosis","volume":"50","author":"Barchiesi","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R48-20230827","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000057666","article-title":"In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds","volume":"48","author":"Nakai","year":"2002","journal-title":"Chemotherapy"},{"key":"R49-20230827","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.diagmicrobio.2014.02.016","article-title":"Candidemia surveillance in Iowa: emergence of echinocandin resistance","volume":"79","author":"Matsumoto","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R50-20230827","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R51-20230827","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"R52-20230827","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible candida glabrata bloodstream infections: data from a large multisite Population-Based Candidemia Surveillance Program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"(Suppl 6)","key":"R53-20230827","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R54-20230827","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1128\/AAC.00136-13","article-title":"Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure","volume":"57","author":"Shields","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R55-20230827","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R56-20230827","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1592\/phco.29.1.17","article-title":"Pharmacology and antifungal properties of anidulafungin, a new echinocandin","volume":"29","author":"Estes","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R57-20230827","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R58-20230827","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000096348","article-title":"The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications","volume":"78","author":"Wagner","year":"2006","journal-title":"Pharmacology"},{"key":"R59-20230827","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Clin Risk Manag"},{"issue":"(Suppl 1)","key":"R60-20230827","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11315550-000000000-00000","article-title":"Pharmacological properties of antifungal drugs with a focus on anidulafungin","volume":"69","author":"Mazzei","year":"2009","journal-title":"Drugs"},{"key":"R61-20230827","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QCO.0b013e3282f1bea3","article-title":"Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies","volume":"20","author":"Gumbo","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"R62-20230827","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: a new echinocandin","volume":"42","author":"Chandrasekar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R63-20230827","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMct060052","article-title":"Echinocandins for candidemia in adults without neutropenia","volume":"355","author":"Bennett","year":"2006","journal-title":"N Engl J Med"},{"key":"R64-20230827","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-2008-1063859","article-title":"Update on echinocandin antifungals","volume":"29","author":"Kauffman","year":"2008","journal-title":"Semin Respir Crit Care Med"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T03:58:37Z","timestamp":1693108717000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000000813","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}